HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and Radiotherapy in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

被引：0
|
作者：
Saba, N. F. [1 ]
Sukari, A. [2 ]
Forget, F. [3 ]
Popovtzer, A. [4 ]
Perez, J. Rubio [5 ]
Park, J. H. [6 ]
Yang, M. H. [7 ]
Sato, M. [8 ,9 ]
Kuipers, M. [10 ]
Ito, R. [8 ,9 ]
Salmioll, S.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Ctr Hosp Ardenne, Libramont, Belgium
[4] Hadassah Med Ctr Ein Kerem, Jerusalem, Israel
[5] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[6] Konkuk Univ, Med Ctr, Seoul, South Korea
[7] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Ctr Immunooncol, Taipei, Taiwan
[8] Merck Biopharma Co Ltd, Merck KGaA, Darmstadt, Germany
[9] Merck Biopharma Co Ltd, Merck KGaA, Tokyo, Japan
[10] Merck KGaA, Healthcare Business, Darmstadt, Germany
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
115
引用
收藏
页码：E21 / E21
页数：1
相关论文
共 50 条
  • [41] Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study
    Zhang, Wencheng
    Yan, Cihui
    Zhang, Tian
    Chen, Xi
    Dong, Jie
    Zhao, Jingjing
    Han, Dong
    Wang, Jun
    Zhao, Gang
    Cao, Fuliang
    Zhou, Dejun
    Jiang, Hongjing
    Tang, Peng
    Zhao, Lujun
    Yuan, Zhiyong
    Wang, Quanren
    Wang, Ping
    Pang, Qingsong
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [42] Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Vugmeyster, Yulia
    Ravula, Abhigyan
    Rouits, Elisabeth
    Diderichsen, Paul Matthias
    Kleijn, Huub Jan
    Koenig, Andre
    Wang, Xiaozhe
    Schroeder, Andreas
    Goteti, Kosalaram
    Venkatakrishnan, Karthik
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (01) : 52 - 61
  • [43] Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer
    Espeli, V.
    Zucca, E.
    Ghielmini, M.
    Giannini, O.
    Salatino, A.
    Martucci, F.
    Richetti, A.
    ORAL ONCOLOGY, 2012, 48 (03) : 266 - 271
  • [44] Feasibility and Response of Concurrent Weekly Docetaxel with Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Raphael, Jomon C.
    Rajesh, I
    Rajesh, B.
    Selvamani, B.
    John, Subhashini
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (03) : XC01 - XC04
  • [45] Cisplatin versus Carboplatin in Radiochemotherapy for Patients with locally advanced Head and Neck Squamous Cell Carcinoma
    Nassif, S.
    Wichmann, J.
    Christiansen, H.
    Steinmann, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S129 - S129
  • [46] Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial
    Bonomo, Pierluigi
    Desideri, Isacco
    Mangoni, Monica
    Saieva, Calogero
    Loi, Mauro
    Becherini, Carlotta
    Cerbai, Cecilia
    Ganovelli, Michele
    Salvestrini, Viola
    Stocchi, Giulia
    Zani, Margherita
    Palomba, Annarita
    Livi, Lorenzo
    RADIOTHERAPY AND ONCOLOGY, 2022, 169 : 64 - 70
  • [47] Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
    Steven F. Powell
    Miroslaw Mazurczak
    Elie G. Dib
    Jonathon S. Bleeker
    Louis H. Geeraerts
    Matthew Tinguely
    Michele M. Lohr
    Steven C. McGraw
    Ashley W. Jensen
    Christie A. Ellison
    Lora J. Black
    Susan E. Puumala
    Valerie J. Reed
    W. Keith Miskimins
    John H. Lee
    William C. Spanos
    Investigational New Drugs, 2022, 40 : 622 - 633
  • [48] Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
    Powell, Steven F.
    Mazurczak, Miroslaw
    Dib, Elie G.
    Bleeker, Jonathon S.
    Geeraerts, Louis H.
    Tinguely, Matthew
    Lohr, Michele M.
    McGraw, Steven C.
    Jensen, Ashley W.
    Ellison, Christie A.
    Black, Lora J.
    Puumala, Susan E.
    Reed, Valerie J.
    Miskimins, W. Keith
    Lee, John H.
    Spanos, William C.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (03) : 622 - 633
  • [49] Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer
    Gulati, Shuchi
    Desai, Janki
    Palackdharry, Sarah M.
    Morris, John C.
    Zhu, Zheng
    Jandarov, Roman
    Riaz, Muhammad K.
    Takiar, Vinita
    Mierzwa, Michelle
    Gutkind, J. Silvio
    Molinolo, Alfredo
    Desai, Pankaj B.
    Sadraei, Nooshin Hashemi
    Wise-Draper, Trisha M.
    CANCER, 2020, 126 (02) : 354 - 362
  • [50] An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
    Sharma, Atul
    Kumar, Manish
    Bhasker, Suman
    Thakar, Alok
    Pramanik, Raja
    Biswas, Ahitagni
    Kumar, Akash
    Sikka, Kapil
    Singh, Amit Chirom
    Mallick, Supriya
    Kumar, Rajeev
    Deo, S. V. S.
    Kakkar, Aanchal
    Baghmar, Saphalta
    Sehrawat, Amit
    Sethi, Pooja
    Kumar, Ashok
    Seth, Sandeep
    Upadhyay, Ashish Dutt
    Thulkar, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345